A Phase 3 Study of F14 for Management of Pain Following Total Knee Replacement
Status:
Not yet recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
This is a Phase 3, randomized, double blind, multicenter study to evaluate the analgesic
efficacy and safety of a single intra-articular dose of F14 (625 mg sustained release
celecoxib) administered concurrent with multimodal analgesia in patients undergoing total
knee replacement surgery, compared to multimodal analgesia alone.